Device Trial Radar · NCT07662824
Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Aug 20, 2026
Primary completion
Aug 20, 2028
Study completion Aug 20, 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation therapy. Urinary incontinence is common after pelvic radiation therapy and can affect daily life and well-being. Access to in-person pelvic floor physical therapy can be limited. The Flyte device is designed for in-home use to deliver a series of mechanical vibrations at a specific frequency while the pelvic floor muscles are contracting and relaxing (i.e., normal, guided Kegel exercises). This treatment is called mechanotherapy. The Flyte device may improve urinary incontinence symptoms, as well as overall quality of life among endometrial and cervical cancer survivors who have undergone radiation therapy.
Conditions
- Cervical Carcinoma
- Endometrial Carcinoma
- Overactive Bladder
- Voiding Disorders
Interventions
Educational InterventionOther
Given educational handouts
InterviewOther
Patients are interviewed on study
Flyte Medical Device Usage and EvaluationDevice
Use Flyte device
Questionnaire AdministrationOther
Participants complete questionnaires on study
ReferralOther
Given referral for in-person pelvic floor physical therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants successfully completing study set up (Feasibility)Time frame: Up to 24 weeks
- Incidence of all serious adverse events (SAEs) including unanticipated adverse device effectsTime frame: Up to 90 days the last administration of study treatment
- Incidence of all device failures and malfunctionsTime frame: Up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.